719 related articles for article (PubMed ID: 16427163)
1. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
Kremer JR; Schneider F; Muller CP
Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
[TBL] [Abstract][Full Text] [Related]
2. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
3. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
[TBL] [Abstract][Full Text] [Related]
5. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
[TBL] [Abstract][Full Text] [Related]
6. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
King SM; Saunders EF; Petric M; Gold R
Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
[TBL] [Abstract][Full Text] [Related]
7. [Immune status against measles and rubella among 4 Chilean groups of different ages].
Valenzuela MT; Vega J; Leal I; Vicente M; Young V; Vera L; Fasce R; Ramírez E
Rev Med Chil; 1999 Mar; 127(3):359-65. PubMed ID: 10436723
[TBL] [Abstract][Full Text] [Related]
8. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
[TBL] [Abstract][Full Text] [Related]
10. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226
[TBL] [Abstract][Full Text] [Related]
11. Immunity against measles and rubella in Massachusetts schoolchildren.
Orenstein WA; Herrmann K; Albrecht P; Bernier R; Holmgreen P; Bart KJ; Hinman AR
Dev Biol Stand; 1986; 65():75-83. PubMed ID: 3556779
[TBL] [Abstract][Full Text] [Related]
12. The national measles and rubella campaign--one year on.
Commun Dis Rep CDR Wkly; 1995 Nov; 5(45):237. PubMed ID: 8541943
[No Abstract] [Full Text] [Related]
13. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
14. [Responses to triple viral and tetanus vaccination in HIV-infected children].
Echeverría Lecuona J; Aldamiz-Echevarría Azuara L; Cilla Eguiluz G; Pérez Trallero E
An Esp Pediatr; 1996 Apr; 44(4):317-20. PubMed ID: 8849078
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of measles and rubella vaccination one year after the nationwide campaign in Shiraz, Iran.
Pourabbas B; Ziyaeyan M; Alborzi A; Mardaneh J
Int J Infect Dis; 2008 Jan; 12(1):43-6. PubMed ID: 17950020
[TBL] [Abstract][Full Text] [Related]
16. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
Gonçalves G; Tavares F; de Andrade HR
Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
[TBL] [Abstract][Full Text] [Related]
17. Persistence of antibody titers after vaccination with rubella virus vaccine ("Cendehill" strain).
Peetermans J; du Pan RM; Huygelen C
Dev Biol Stand; 1979; 43():361-5. PubMed ID: 520683
[TBL] [Abstract][Full Text] [Related]
18. Measles seroepidemiology among adolescents and young adults: response to revaccination.
Saffar MJ; Alraza-Amiri M; Ajami A; Baba-Mahmoodi F; Khalilian AR; Vahidshahi C; Shamsizadeh A
East Mediterr Health J; 2006 Sep; 12(5):573-81. PubMed ID: 17333796
[TBL] [Abstract][Full Text] [Related]
19. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
[TBL] [Abstract][Full Text] [Related]
20. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
Davidkin I; Valle M; Julkunen I
Vaccine; 1995 Nov; 13(16):1617-22. PubMed ID: 8578851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
